These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8133452)

  • 21. [Treatment by antiviral drugs of HIV-infected patients].
    Mayaud C
    Rev Pneumol Clin; 1993; 49(2):71-4. PubMed ID: 8272744
    [No Abstract]   [Full Text] [Related]  

  • 22. Update on HIV chemoprophylaxis following exposure.
    Flaxman NA; Reed HS
    J Tenn Dent Assoc; 1997 Oct; 77(4):42-4. PubMed ID: 9520762
    [No Abstract]   [Full Text] [Related]  

  • 23. ddC (zalcitabine).
    Skowron G
    Adv Exp Med Biol; 1996; 394():257-69. PubMed ID: 8815690
    [No Abstract]   [Full Text] [Related]  

  • 24. [AIDS therapy with reverse transcriptase inhibitors].
    Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():316-26. PubMed ID: 7505849
    [No Abstract]   [Full Text] [Related]  

  • 25. In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
    Ostashewski PM; Houston SC; Robertson JA
    Lancet; 1993 Nov; 342(8881):1242-3. PubMed ID: 7901563
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zalcitabine and didanosine.
    Lipsky JJ
    Lancet; 1993 Jan; 341(8836):30-2. PubMed ID: 8093278
    [No Abstract]   [Full Text] [Related]  

  • 28. Human immunodeficiency virus infection in children.
    Hoernle EH; Reid TE
    Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agents for treating human immunodeficiency virus infection.
    Acosta EP; Fletcher CV
    Am J Hosp Pharm; 1994 Sep; 51(18):2251-67; quiz 2286-7. PubMed ID: 7801986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages.
    Degré M; Beck S
    Chemotherapy; 1994; 40(3):201-8. PubMed ID: 7515781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
    Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
    Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
    [No Abstract]   [Full Text] [Related]  

  • 33. Resistance, drug failure, and disease progression.
    Richman DD
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):901-5. PubMed ID: 7811540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When the unthinkable happens: post-exposure prophylaxis of HIV-contaminated percutaneous injuries.
    Petty TL
    J Can Dent Assoc; 1999 May; 65(5):293-4. PubMed ID: 10380407
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy for human immunodeficiency virus infection -- what have we learned?
    Corey L; Holmes KK
    N Engl J Med; 1996 Oct; 335(15):1142-4. PubMed ID: 8813046
    [No Abstract]   [Full Text] [Related]  

  • 36. Most common prescribing error in postexposure prophylaxis of HIV/AIDS.
    Mahajan A; Sharma H; Bhagat A; Tandon VR; Sharma R; Sharma S
    J Assoc Physicians India; 2007 Mar; 55():246-7. PubMed ID: 17598343
    [No Abstract]   [Full Text] [Related]  

  • 37. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen.
    Beltrami EM; Luo CC; de la Torre N; Cardo DM
    Infect Control Hosp Epidemiol; 2002 Jun; 23(6):345-8. PubMed ID: 12083242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
    Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination therapies with anti-retroviral agents in HIV and AIDS infections].
    Fernández-Cruz E
    Rev Clin Esp; 1991 Oct; 189(6):253-5. PubMed ID: 1722345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.